2025 · 1st Quarter (Jan 1 - Mar 31)

FRESENIUS KABI USA LLC

Filed by FRESENIUS KABI USA LLC.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: May 6, 2025
Income: Not reported
Expenses: $712,941.00
Registrant: FRESENIUS KABI USA LLC
Client: FRESENIUS KABI USA LLC
Filing UUID: 54e55f28-7f05-4c46-b9fb-2b3775dfe88d
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MAN · Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launch

TAR · Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices

TRD · Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, made in America

PHA · Pharmacy

PBM reform, including spread pricing, AWP policy, ASP policy

MMM · Medicare/Medicaid

PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty

TAX · Taxation/Internal Revenue Code

BEAT, AMT, U.S. manufacturing incentives

HCR · Health Issues

Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.